Instituto Rosenbusch (BUE:ROSE) Beneish M-Score: -9.31 (As of Jun. 26, 2026)


BUE:ROSE Instituto Rosenbusch SA BUE:ROSE
39 GF Score
Price ARS160.50
GF Value ARS61.70
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Instituto Rosenbusch Beneish M-Score?

Instituto Rosenbusch BUE:ROSE -1.53% 39 Beneish M-Score is -9.31 as of Jun. 26, 2026. GuruFocus rates BUE:ROSE with a GF Score™ of 39/100 and a GF Value™ of ARS61.70 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 911 Drug Manufacturers companies, Instituto Rosenbusch ranks better than 99.12% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -9.31 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Instituto Rosenbusch's Beneish M-Score or its related term are showing as below:

BUE:ROSE' s Beneish M-Score Range Over the Past 10 Years
Min: -9.31   Med: -2.73   Max: -0.73
Current: -9.31

During the past 13 years, the highest Beneish M-Score of Instituto Rosenbusch was -0.73. The lowest was -9.31. And the median was -2.73.


Instituto Rosenbusch Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Instituto Rosenbusch's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instituto Rosenbusch Beneish M-Score Chart

Instituto Rosenbusch Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.88 -4.76 -1.62 -4.26 -9.31

Instituto Rosenbusch Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.26 -4.83 -5.70 -1.36 -9.31

BUE:ROSE vs ZTS, UTHR, VTRS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Instituto Rosenbusch Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Instituto Rosenbusch's Beneish M-Score falls into.


BUE:ROSE
39GF Score
Instituto Rosenbusch SA BUE:ROSE
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Instituto Rosenbusch Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Instituto Rosenbusch for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.2501+0.528 * -4.9527+0.404 * 1.2526+0.892 * 0.5883+0.115 * -0.5252
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 2.0824+4.679 * -0.646524-0.327 * 1.7969
=-9.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was ARS1,658 Mil.
Revenue was 2130.381 + 1747.214 + 1409.192 + 1116.807 = ARS6,404 Mil.
Gross Profit was 292.037 + -422.697 + -384.103 + -84.05 = ARS-599 Mil.
Total Current Assets was ARS5,733 Mil.
Total Assets was ARS7,745 Mil.
Property, Plant and Equipment(Net PPE) was ARS1,992 Mil.
Depreciation, Depletion and Amortization(DDA) was ARS163 Mil.
Selling, General, & Admin. Expense(SGA) was ARS1,104 Mil.
Total Current Liabilities was ARS6,605 Mil.
Long-Term Debt & Capital Lease Obligation was ARS931 Mil.
Net Income was -1353.546 + -1386.39 + -1267.732 + -590.068 = ARS-4,598 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ARS0 Mil.
Cash Flow from Operations was 811.184 + -84.581 + -839.054 + 522.337 = ARS410 Mil.
Total Receivables was ARS2,255 Mil.
Revenue was 2380.064 + 2710.475 + 2739.387 + 3055.63 = ARS10,886 Mil.
Gross Profit was 1195.048 + 7741.827 + -6033.168 + 2137.771 = ARS5,041 Mil.
Total Current Assets was ARS7,758 Mil.
Total Assets was ARS9,921 Mil.
Property, Plant and Equipment(Net PPE) was ARS2,143 Mil.
Depreciation, Depletion and Amortization(DDA) was ARS-82 Mil.
Selling, General, & Admin. Expense(SGA) was ARS901 Mil.
Total Current Liabilities was ARS4,329 Mil.
Long-Term Debt & Capital Lease Obligation was ARS1,043 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1658.377 / 6403.594) / (2255.171 / 10885.556)
=0.258976 / 0.207171
=1.2501

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(5041.478 / 10885.556) / (-598.813 / 6403.594)
=0.463135 / -0.093512
=-4.9527

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (5732.98 + 1992.118) / 7745.455) / (1 - (7757.803 + 2142.81) / 9921.43)
=0.002628 / 0.002098
=1.2526

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=6403.594 / 10885.556
=0.5883

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(-81.993 / (-81.993 + 2142.81)) / (163.286 / (163.286 + 1992.118))
=-0.039787 / 0.075757
=-0.5252

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1104.055 / 6403.594) / (901.263 / 10885.556)
=0.172412 / 0.082794
=2.0824

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((931.022 + 6605.345) / 7745.455) / ((1043.409 + 4328.968) / 9921.43)
=0.973005 / 0.541492
=1.7969

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-4597.736 - 0 - 409.886) / 7745.455
=-0.646524

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Instituto Rosenbusch has a M-score of -9.31 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -9.31 mean?
Instituto Rosenbusch (BUE:ROSE) has a Beneish M-Score of -9.31 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Instituto Rosenbusch and its competitors. According to the industry distribution chart, Instituto Rosenbusch ranks #8 out of 911 companies in the Drug Manufacturers industry, placing it in the top 0.90000000000001%.
Is Instituto Rosenbusch's Beneish M-Score too high?
Instituto Rosenbusch's current Beneish M-Score is -9.31. Based on the distribution chart, Instituto Rosenbusch ranks #8 out of 911 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Instituto Rosenbusch has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Instituto Rosenbusch ranks #8 out of 911 companies for Beneish M-Score. This places Instituto Rosenbusch in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Instituto Rosenbusch and its competitors. Instituto Rosenbusch's current Beneish M-Score is -9.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS61.70, compared to a current price of ARS160.50 — trading 160.1% above its estimated fair value. The current Beneish M-Score is -9.31. Instituto Rosenbusch's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current Beneish M-Score is -9.31 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?

Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued. The current stock price of ARS160.50 is trading 160.1% above its estimated GF Value™ of ARS61.70. GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.

Key valuation signals for BUE:ROSE:

  • Beneish M-Score: -9.31
  • GF Value™: ARS61.70 vs. price of ARS160.50 (160.1% above fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Instituto Rosenbusch Business Description

Address Hipolito Yrigoyen 1628, Buenos Aires, ARG, C1089AAF
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
39GF Score

Get the complete analysis for BUE:ROSE

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS160.50
Price
ARS61.70
GF Value